Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Imugene ( (AU:IMU) ) has provided an announcement.
Imugene Limited has announced the quotation of additional securities on the Australian Securities Exchange (ASX), with a total of 532,182 ordinary fully paid shares being issued. This move reflects the company’s ongoing efforts to strengthen its financial position and enhance its market presence, potentially impacting its operational capabilities and investor confidence.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited operates in the biotechnology industry, focusing on the development of immuno-oncology therapies. The company specializes in creating innovative cancer treatments that harness the immune system to target and eradicate tumors, aiming to improve patient outcomes in the oncology market.
Average Trading Volume: 629,188
Technical Sentiment Signal: Sell
Current Market Cap: A$82.4M
For an in-depth examination of IMU stock, go to TipRanks’ Overview page.